Robert L. Ferris, MD, PhD | Authors


After More Than 30 Years, Research on HER2 Continues to Expand Our Understanding of Cancer

July 03, 2021

It has taken some decades, but the identification of targets such as HER2 has enabled us to segregate cancers into different subtypes, develop novel therapeutic strategies, and eventually understand the biology distinguishing one group of patients from another, says Robert L. Ferris, MD, PhD.

Lessons From Clinical Trial Setbacks Lead to Next Phase of Oncologic Advances

October 04, 2020

In the wake of the enthusiasm around cancer immunotherapy trial results—with several positive trials presented annually at each American Society of Clinical Oncology meeting in more and more diseases over several years—setbacks have served as a grim reminder that our work is not finished.

Educational Interactions Among Oncologists Remain a Subtle Loss During COVID-19 Pandemic

July 18, 2020

Exciting new knowledge and a more exquisite understanding of the role of tumor cell biology and the tumor microenvironment have driven the fields of precision oncology/genomics-based medicine and immuno-oncology/cancer immunotherapy.